Skip to Main Content
BLACK FRIDAY SALE

60% off Quiver Premium for new subscribers

...

Use Promo Code:

BLACKFRIDAY26
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Benitec Biopharma Posts $12.9 Million First-Quarter Net Loss

None

Benitec Biopharma (BNTC) reported a net loss of $12.9 million, or $0.26 per basic and diluted share, for the fiscal first quarter ended September 30, 2026. The company had $176.5 million in cash and cash equivalents at quarter-end.

The company also reported interim Phase 1b/2a data for BB-301 in OPMD-related dysphagia, with a 100% responder rate across Cohort 1 and Cohort 2 patients. Benitec said it expects to finalize the pivotal-study design in the first calendar quarter of 2027 and begin the trial in mid-2027.

  • Total operating expenses were $14.5 million, including $8.6 million in research and development expense.
  • Net loss was $12.925 million, compared with $8.965 million in the prior-year quarter.
  • Basic and diluted net loss per share was $0.26, compared with $0.22 a year earlier.
  • Benitec plans to change its fiscal year-end from June 30 to December 31.
  • No serious adverse events have been reported in patients treated with BB-301 to date.

$BNTC Hedge Fund Activity

We have seen 41 institutional investors add shares of $BNTC stock to their portfolio, and 37 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles